Back to search

Article

Proteomic profiling of advanced hepatocellular carcinoma identifies predictive signatures of response to treatments

2025-01-04

Abstract excerpt

<h4>Purpose</h4> Hepatocellular carcinoma (HCC) is the most common form of liver cancer with a bad prognosis in case of advanced HCC, only eligible for palliative systemic therapies. After a decade of exclusive sorafenib monotherapy, with a response rate of <10%, the advent of immunotherapies represents a revolution in HCC. The combination of atezolizumab/bevacizumab is recommended as the first-line systemic trea...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
f56c30a3-9f4b-5566-b41e-617008025107
DOI
10.1101/2025.01.03.631224
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Proteomic profiling of advanced hepatocellular carcinoma identifies predictive signatures of response to treatmentsDOI 10.1101/2025.01.03.631224
Multi-omics of sorafenib responsiveness in HCC patientsSemantic proximity
Proteome Expression Profile for Red Blood Cells Enables Diagnostics for Hepatocellular CarcinomaSemantic proximity
Proteo-genomic characterization of virus-associated liver cancers reveals potential subtypes and therapeutic targets.Semantic proximity
Multiomics identifies metabolic subtypes based on fatty acid degradation allocating personalized treatment in hepatocellular carcinomaSemantic proximity
Multi-omics analysis reveals the role of tumor-infiltrating CD4+CCR7+ T cells in EGFR antibody resistance and prognosis of hepatocellular carcinomaSemantic proximity
The predictive value of next generation sequencing for matching advanced hepatocellular carcinoma patients to targeted and immunotherapy.Semantic proximity
Early Identification of At-Risk Patients: Proteomic Signature Predicts Progression to Decompensated CirrhosisSemantic proximity
Screening of HRas, RRas and FOS as Potential Pharmacodynamic Candidates for the Treatment of Hepatocellular CarcinomaSemantic proximity
Therapeutic targets for hepatocellular carcinoma identified using proteomics and Mendelian randomizationSemantic proximity
ADH4 is a TP53-associated immunometabolic signature for prediction of prognosis in hepatocellular carcinomaSemantic proximity
Exploration of Practical Biomarkers for Systemic Drug Therapy for Hepatocellular CarcinomaSemantic proximity
Multiple “Omics” data-based biomarker screening for hepatocellular carcinoma diagnosisSemantic proximity
Select a neighboring publication to make it the new centre.